PharmaEssentia announced during a press conference on the 25th that its primary objective for 2025 is to advance the Phase III global clinical trial of its blood cancer drug Ropeg for the treatment of essential thrombocythemia (ET). The company plans to release key efficacy indicators and data collection results early next year. If the results are favorable, Ropeg could be launched as early as 2026, targeting a market larger than its currently marketed therapy for polycythemia vera (PV).

In response to the growing global PV market, PharmaEssentia stated that its existing facilities in Taichung—comprising a PEG production plant, a biologics (DS) manufacturing facility, and a sterile injection filling facility—currently serve over 10,000 patients. However, the company is expanding its production capacity with a second production line, which will double capacity to meet the needs of over 20,000 patients. In addition to its Taichung facilities, the company is constructing new plants in Zhubei and Houli, expected to be completed by 2025.

PharmaEssentia emphasized its ambition to become a global leader in the treatment of myeloproliferative neoplasms (MPN). While Ropeg has already been developed as a PV treatment, the new drug for ET is expected to launch in two years. Additionally, the company is developing a treatment for myelofibrosis (MF), further solidifying its position in the MPN therapeutic space.

Resource: 藥華藥血癌藥 拚三期臨床